Direxion NASDAQ 100 Equal Weighted Index Shares vs Vir Biotechnology Inc. Common Stock — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.79 (market cap $1.46B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vir Biotechnology Inc. Common Stock is the larger of the two by market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is more actively traded (175,669 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 50 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| QQQE | VIR | |
|---|---|---|
Market Cap | $1.46B | $1.80B |
Volume | 175,669 | 1,782,836 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $11.78 |
52-Week Low | $96.06 | $5.12 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $120.45, down 0.4% on the day with a bearish technical signal from moving averages. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning over the next twelve months.
The equal-weight approach provides diversification benefits amid tech sector volatility, though the bearish technical trend and neutral oscillators suggest near-term consolidation. Key risks include NASDAQ concentration and market volatility, while the strategy appeals to investors seeking reduced tech exposure within large-cap growth stocks.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →